Across the AusBiotech International Conference and AusMedtech Conference delegates have access to over 60 sessions, delivered by more than 250 speakers. The keynote speakers, orators and key panellists below are just the beginning, with more still to be announced.
Global CMO for Diagnosis & Treatment,
Philips
Dr Atul Gupta is Global Chief Medical Officer for Diagnosis and Treatment at Philips and a practising physician with more than 20 years of clinical experience. He shapes patient-centred innovation across radiology, cardiology, neurology and oncology, with a focus on AI, robotics and augmented reality. His work explores how connected technologies, global partnerships and coordinated care can improve access and outcomes at scale, particularly for time-critical conditions such as stroke.
CEO & Managing Director (Founder),
ANDHealth
Bronwyn is a life sciences and technology executive with more than 20 years’ experience spanning commercialisation, corporate development, investment and advocacy. She founded ANDHealth in 2017, building it into Australia’s leading health technology accelerator, incubator and commercialisation services organisation. ANDHealth manages more than $52 million and co-manages a further $100 million in non-dilutive investment capital. Companies participating in its programs have raised over $224 million, created more than 530 jobs and reached 3.4 million patients.
Founder & CEO,
Providence Therapeutics
Bradley Sorenson is Founder and CEO of Providence Therapeutics, a leading Canadian mRNA company developing personalised cancer vaccines. Inspired by his son Adam’s cancer diagnosis, he has dedicated his work to advancing new therapeutic approaches for patients. Providence Therapeutics is partnering with Gold Coast-based Southern RNA to manufacture next-generation mRNA therapies, demonstrating how international collaboration can accelerate innovation and create global patient impact.
President, CSO, Co-founder,
Lin BioScience & Belite Bio
Dr Irene Wang is a scientist and biotechnology leader who has taken two drug candidates from discovery to regulatory submission. As President and Chief Scientific Officer of Lin BioScience and Co-founder of Belite Bio, she combines world-class science with commercial strategy. Dr Wang led Tinlarebant (LBS-008) from early-phase clinical trials to submission, securing FDA Orphan Drug and Fast Track designations, and continues to advance innovation with global patient impact.
Founder & MD,
SYNthesis Bioventures
Prof. Andrew Wilks is a pioneering scientist, entrepreneur and industry leader whose discovery of the Janus kinase family helped define the JAK/STAT signalling pathway, now underpinning therapies used worldwide. He co-invented several clinically trialled drug candidates and has founded or co-founded 15 companies, Professor Wilks has received the Prime Minister’s Prize for Innovation, is a Fellow of three Australian learned academies and will deliver the 2026 Millis Oration, sponsored by CSL.
Director
Burns Service of Western Australia
Professor Fiona Wood AO is an internationally recognised burns surgeon and researcher with over three decades of experience. She co-invented spray-on skin cell technology (ReCell), transforming burn treatment worldwide. She is Director of the Burns Service of Western Australia, Winthrop Professor at UWA, and co-founder and director of the Fiona Wood Foundation. Professor Fiona Wood AO will deliver the 2026 Depaz Oration, sponsored by Sanofi.
There’s so much more to uncover, with one registration unlocking every session in the AusMedtech and International Conferences.
AusMedtech and the Ausbiotech International Conference registration is now open at Standard pricing. Every registrant will experience both conferences seamlessly, from one day to a whole week. Register by 11.59pm AEST on October 2nd to save up to $300.
Receive the latest industry updates, events and opportunities straight to your inbox.
Sign up for updates